Pre-market futures are up slightly at this hour. Markets look to rebound off a three-day losing streak on the S&P 500 and Nasdaq; the blue-chip Dow outperformed the field yesterday, closing +0.17%. Major indices are all lower over the past month, from -1.7% (tech-heavy Nasdaq) to -2.9% (small-cap Russell 2000). Year to date, only the Russell is back in the red — the Dow is +0.3%, the S&P is +6.7% and the Nasdaq is +7.2%. Late March highs — including all-time S&P levels — have given way to profit-taking and ...

Wednesday, April 17th, 2024Pre-market futures are up slightly at this hour. Markets look to rebound off a three-day losing streak on the S&P 500 and Nasdaq; the blue-chip Dow outperformed the field yesterday, closing +0.17%. Major indices are all lower over the past month, from -1.7% (tech-heavy Nasdaq) to -2.9% (small-cap Russell 2000). Year to date, only the Russell is back in the red — the Dow is +0.3%, the S&P is +6.7% and the Nasdaq is +7.2%. Late March highs — including all-time S&P levels — have give ...

Abbott Laboratories (ABT) reported first-quarter 2024 adjusted earnings per share (EPS) of 98 cents, which topped the Zacks Consensus Estimate by 2.1%. However, the adjusted figure decreased 4.9% from the prior-year quarter’s level. The quarter’s adjustments include 28 cents of certain non-recurring items.GAAP EPS came in at 70 cents, down 6.7% year over year.First-quarter worldwide sales of $9.96 billion were up 2.2% year over year on a reported basis. The top line exceeded the Zacks Consensus Estimate by ...

For the quarter ended March 2024, Abbott (ABT) reported revenue of $9.96 billion, up 2.2% over the same period last year. EPS came in at $0.98, compared to $1.03 in the year-ago quarter.The reported revenue represents a surprise of +1.15% over the Zacks Consensus Estimate of $9.85 billion. With the consensus EPS estimate being $0.96, the EPS surprise was +2.08%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations ...

Abbott (ABT) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.08%. A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $1.19 per share when it actually produced earnings of $1.19, delivering no surprise.Over the last four ...

Abbott Laboratories on April 17 reported a 2.2% rise of $10 billion in its 2024 first-quarter sales which includes the impact of the anticipated decline in COVID-19 testing-related sales as compared to the previous year.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Organic sales grew for the underlying base business of 10.8%, which represents the fifth consecutive quarter of double-digit growth. According to the report in the first quarter of 2024, ...

Financial Performance - Abbott reported first-quarter 2024 sales of $10.0 billion, reflecting a 2.2% increase year-over-year, with organic sales growth of 10.8% for the underlying base business[1]. - The company achieved a GAAP diluted EPS of $0.70 and an adjusted diluted EPS of $0.98, with full-year 2024 diluted EPS guidance narrowed to a range of $3.25 to $3.40[2]. - Abbott's full-year 2024 organic sales growth guidance, excluding COVID-19 testing-related sales, is now projected at 8.5% to 10.0%[2]. - Total worldwide sales for Q1 2024 were $9.964 billion, a 2.2% increase from $9.747 billion in Q1 2023[18]. - Net earnings for Q1 2024 were $1.225 billion, a decrease of 7.0% compared to $1.318 billion in Q1 2023[22]. - Diluted earnings per share for Q1 2024 were $0.70, down 6.7% from $0.75 in Q1 2023[22]. - Operating earnings for Q1 2024 were $1.386 billion, down 8.1% from $1.509 billion in Q1 2023[22]. - U.S. revenue decreased by 2.1% to $3,846 million in Q1 2024 from $3,928 million in Q1 2023[33]. - International revenue increased by 5.2% to $6,118 million in Q1 2024, up from $5,819 million in Q1 2023[33]. - Organic growth for the total company was reported at 4.7% for Q1 2024[33]. Sales Performance by Segment - Worldwide Nutrition sales increased 5.1% on a reported basis and 7.7% on an organic basis in Q1 2024, with Pediatric Nutrition sales growing 9.2% reported and 10.5% organic[5][6]. - Diagnostics sales were reported at $2.214 billion, a decline of 17.6% year-over-year, primarily due to a decrease in COVID-19 testing sales, which were $204 million compared to $730 million in the prior year[7][8]. - Established Pharmaceuticals sales increased 3.1% on a reported basis and 13.7% on an organic basis, driven by growth in key emerging markets[9][10]. - Medical Devices sales reached $4.453 billion, reflecting a 14.2% increase on a reported basis and 14.3% organic growth, with double-digit growth in both U.S. and international markets[11]. - FreeStyle Libre sales in Diabetes Care reached $1.5 billion, reflecting a 22.4% growth on a reported basis and 23.3% on an organic basis[12]. - In Electrophysiology, international sales grew 18.9% reported and 23.0% organic, with Europe seeing a 20.4% organic growth[12]. - Total Medical Devices revenue reached $4,453 million in Q1 2024, a 14.2% increase from $3,900 million in Q1 2023[33]. - Vascular segment revenue was $689 million in Q1 2024, reflecting an 11.7% increase compared to $617 million in Q1 2023[33]. - The international Medical Devices segment showed a strong organic growth of 16.1% in Q1 2024[33]. Research and Development - Research and development expenses increased by 4.5% to $684 million in Q1 2024 compared to $654 million in Q1 2023[22]. Corporate Actions - Abbott launched the Protality™ brand, a new high-protein nutrition shake, and received FDA approval for the TriClip™ treatment for tricuspid regurgitation in April 2024[2]. - The company completed enrollment in the Volt CE Mark clinical study for the Volt™ Pulsed Field Ablation System, aimed at treating heart rhythm disorders[2]. - The company declared a quarterly dividend of $0.55 per share, marking 401 consecutive quarterly dividends and 52 years of dividend increases[14]. Costs and Expenses - Abbott's total operating costs and expenses rose by 4.1% to $8.578 billion in Q1 2024 from $8.238 billion in Q1 2023[22]. - The company incurred $518 million in specified items, including $472 million for intangible amortization and $42 million for restructuring initiatives[35]. - Abbott's gross margin was impacted by acquisition-related expenses and restructuring costs totaling $518 million[35].

Sales of $10.0 billion driven by strong underlying base business performance Reported sales increased 2.2 percent, which includes the impact from the anticipated decline in COVID-19 testing-related sales versus prior year Organic sales growth for underlying base business of 10.8 percent, which represents the fifth consecutive quarter of double-digit growth1 ABBOTT PARK, Ill., April 17, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2024. ...

Tuesday, April 16th, 2024Market indices fluctuated today. The S&P 500 and Nasdaq were in-line throughout the day, right around breakeven (-0.21% and -0.12%, respectively). The Dow stayed in the green for all but a few minutes on the session, finishing +0.17%. The Russell 2000 only spent a moment out of negative territory today, reaching the closing bell at -0.42%. Fed Chair Jerome Powell’s comments today solidified that monetary policy is seriously considering delaying its first rate cut until economic repo ...

LAS VEGAS, NEVADA - JANUARY 10: An Abbott logo is displayed at the company's booth during CES 2024 ... [+] at the Las Vegas Convention Center on January 10, 2024 in Las Vegas, Nevada. (Photo by Ethan Miller/Getty Images)Getty ImagesAbbott (NYSE: ABT) will report its Q1 2024 results on Wednesday, April 17. We expect the company to post revenue of $9.9 billion and earnings of $0.95 on a per share and adjusted basis, aligning with the street expectations. We expect a low double-digit uptick in sales for the co ...